Hereditary Breast Cancer Prevention
Shaare Zedek Medical Center is involved in clinical research focused on reducing the risk of breast cancer in women with a BRCA1 germline mutation, with attention to both invasive disease and ductal carcinoma in situ (DCIS).
- BRCA1-associated cancer risk
- Breast cancer prevention
- Hereditary cancer susceptibility
The research activity centres on oncology and genetic cancer predisposition, reflecting interest in preventive strategies for women at elevated inherited risk.
Genetic Risk and Preventive Oncology
The sponsored study examines a prevention-oriented approach for women carrying pathogenic BRCA1 variants, linking molecular genetics with cancer prevention in a high-risk female population.
- Inherited cancer syndromes
- Risk reduction in women
- Preventive breast oncology
Research is aligned with clinical interest in identifying interventions for germline mutation carriers before the onset of malignancy.
Bone-Targeted Cancer Prevention
The trial activity includes evaluation of denosumab in the context of breast cancer prevention, indicating interest in bone-targeted therapy and its possible role in modifying cancer risk.
- Denosumab
- Bone biology
- Cancer risk modulation
This area connects therapeutic prevention with mechanisms relevant to women at inherited oncologic risk.
